New partnership aims to streamline international clinical trial recruitment by addressing travel, finance, and access burdens for patients and families.

In a move to address long-standing barriers in international clinical trial participation, healthtech company myTomorrows has partnered with patient support specialist Scout Clinical to provide cross-border logistical and financial services for trial participants. The companies announced the collaboration on April 15, 2025, stating it aims to support both trial sponsors and patients by easing the complex journey many face in accessing experimental treatments beyond national borders.

Recruiting patients across borders remains a persistent challenge for biopharmaceutical sponsors, particularly in trials involving rare diseases or strict eligibility criteria. Limited local patient populations often mean that sponsors must recruit globally, but this can lead to delays, increased costs, and reduced diversity due to bureaucratic, financial, and cultural obstacles. These include visa requirements, fragmented trial registries, language barriers, and difficulties in arranging and reimbursing travel, accommodation, or family support.

The partnership brings together myTomorrows’ AI-based trial-matching platform and patient navigator service, with Scout Clinical’s operational logistics, which includes assistance with travel, accommodation, pre-funded expense cards, and regulatory navigation. According to myTomorrows, their AI tool can identify potentially suitable trials in seconds, significantly reducing the time physicians spend checking eligibility criteria manually. The Dutch-headquartered company, with additional offices in New York, has so far supported over 15,000 patients and 2,400 physicians across more than 120 countries.

Meanwhile, Scout Clinical, a US-based company with operations in 109 countries, brings three decades of experience in managing patient-facing logistics for life sciences companies. Through Scout’s platform, patients and caregivers gain access to personalized travel plans, housing solutions, and financial assistance, removing a layer of burden that often prevents participation.

In a statement, Scout CEO Moisha Platto said the integration of services would “simplify enrollment and enhance the overall experience for patients and their families,” allowing sites to manage international patients more efficiently and improving retention once patients are enrolled.

Michel van Harten, MD, CEO of myTomorrows, described the joint initiative as a way to overcome “the geographic silos of traditional trials,” enabling broader access to experimental treatments regardless of a patient’s location or socioeconomic status.

The companies said the partnership has already been implemented in select trial programs and is expected to expand to include both domestic and cross-border support where site proximity remains a challenge.

By addressing some of the most cited pain points in international trial participation, the collaboration reflects a broader industry push toward more inclusive, patient-centric clinical research strategies.